

Amendments to the Claims:

The following listing of claims below will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of treating a pulmonary disease comprising the administration of a therapeutically effective amount of a pharmaceutical composition to a subject in need of such treatment, wherein the pulmonary disease has as a symptom the excess formation of mucus secretions in the airways, said pulmonary disease is selected from the group consisting of chronic bronchitis, acute asthma, cystic fibrosis, chronic obstructive pulmonary disease and bronchiectasis, said composition comprising one or more mucoactive agents which assist mucous clearance through one or more of the following mechanisms: reducing cross-linking within the mucus, diluting the mucus, and digesting naked DNA and cell debris within the mucus, wherein the composition comprises one or more glycosaminoglycans and an amino acid, and wherein the composition comprises 2% or more w/w of amino acid.

Claim 2 (original): A composition as claimed in claim 1, wherein one or more of the mucoactive agents are able to reduce inflammation.

Claim 3 (previously presented): A composition as claimed in claim 1, comprising two or more mucoactive agents.

Claim 4 (cancelled).

Claim 5 (cancelled).

Claim 6 (previously presented): A composition as claimed in claim 1, wherein the glycosaminoglycan is one or more of the following: heparin and a heparinoid.

Claim 7 (previously presented): A composition as claimed in claim 6, wherein the heparinoid is one or more of the following: danaparoid sodium and dermatan sulphate.

Claim 8 (original): A composition as claimed in claim 6, wherein the heparinoid contains heparin, dermatan sulphate and chondroitin sulphate.

Claim 9 (previously presented): A composition as claimed in claim 1, comprising a compound selected from the group consisting of: sulfated glucosaminoglycans, glycosaminoglycan polysulphate compounds, and sulfated mucopolysaccharides.

Claim 10 (previously presented): A composition as claimed in claim 1, further comprising one or more of: a monosaccharide, a disaccharide, and an oligosaccharide.

Claim 11 (previously presented): A composition as claimed in claim 1, further comprising one or more of: dextran, dextrin, glucose and mannitol.

Claim 12 (cancelled).

Claim 13 (previously presented): A composition as claimed in claim 1, further comprising one or more of: rhDNase, gelsolin and thymosin β 4.

Claim 14 (previously presented): A composition as claimed claim 1, further comprising one or more of: acetylcysteine and Nacystelyn.

Claim 15 (previously presented): A composition as claimed in claim 1, wherein the composition is a dry powder for pulmonary inhalation.

Claim 16 (previously presented): A composition as claimed in claim 15, wherein the composition has a less than 5 μ m fine particle fraction of at least 50%.

Claim 17 (currently amended): A composition as claimed in claim 15, wherein the composition has a fine particle fraction ~~dose~~ of between 50 and 90%.

Claim 18 (previously presented): A composition as claimed in claim 15, comprising particles of at least one mucoactive agent and a force control agent.

Claim 19 (previously presented): A composition as claimed in claim 18, wherein the force control agent is selected from the group consisting of: an amino acid peptide or derivatives thereof, a phospholipid and a metal stearate.

Claim 20 (previously presented): A composition as claimed in claim 19, wherein the force control agent is selected from the group consisting of: leucine, lysine, cysteine, and mixtures thereof.

Claim 21 (previously presented): A composition as claimed in claim 18, wherein the force control agent is included in an amount of up to 50% w/w.

Claim 22 (previously presented): A composition as claimed in claim 15, wherein the composition comprises particles of mucoactive agent having a MMAD of less than 10 μ m.

Claim 23 (previously presented): A composition as claimed in claim 22, wherein the particles of mucoactive agent have a MMAD of from about 2 to about 5 μ m.

Claim 24 (previously presented): A composition as claimed in claim 15, wherein the composition further comprises carrier particles.

Claim 25 (previously presented): A pharmaceutical composition as claimed in claim 1, for the treatment of a human patient in need of such therapy.

Claim 26 (original): A pharmaceutical composition as claimed in claim 25, for treating a pulmonary disease.

Claim 27 (previously presented): A pharmaceutical composition as claimed in claim 26, wherein the pulmonary disease is selected from the group consisting of: hypersecretion of mucus and abnormal viscoelasticity of mucus.

Claim 28 (previously presented): A pharmaceutical composition as claimed in claim 26, wherein the pulmonary disease is selected from the group consisting of: chronic bronchitis, acute asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and bronchiectasis.

Claim 29 (cancelled).

Claim 30 (previously presented): A method of producing particles for use in a composition as claimed in claim 1, the method comprising spray drying the one or more mucoactive agents in a spray drier.

Claim 31 (previously presented): A method as claimed in claim 30, wherein the step of spray drying further includes producing droplets moving at a controlled velocity.

Claim 32 (original): A method as claimed in claim 31, wherein the velocity of droplets at 5mm from their point of generation is less than 20m/s.

Claim 33 (previously presented): A method as claimed in claim 31, wherein the spray drier comprises an ultrasonic nebuliser.

Claim 34 (previously presented): A method as claimed in claim 31, wherein the one or more mucoactive agents are co-spray dried with a force control agent.

Claim 35 (previously presented): A method of producing particles for use in a composition as claimed in claim 1, the method comprising the step of jet milling particles

of the one or more mucoactive agents in the presence of an element selected from the group consisting of: air, a compressible gas, and a fluid.

Claim 36 (original): A method as claimed in claim 35, wherein the particles are jet milled in the presence of a force control agent.

Claim 37 (previously presented): A method as claimed in claim 35, wherein the step of jet milling is carried out at an inlet pressure of between 0.1 and 3 bar.

Claim 38 (previously presented): A method as claimed in claim 35, wherein the step of jet milling is carried out at an inlet pressure of between 3 and 12 bar.

Claim 39 (previously presented): A method as claimed in claim 35, wherein at least 90% by volume of the active particles are less than 20 μ m in diameter prior to jet milling.

Claim 40 (previously presented): A method as claimed in claim 30, wherein 90% of the resulting dried particles have a size of less than 10 μ m, as measured by laser diffraction.

Claim 41 (previously presented): The composition as claimed in claim 15, wherein said composition has a fine particle fraction of between 70 and 99%.

Claim 42 (previously presented): The composition as claimed in claim 15, wherein said composition has a fine particle fraction of between 80 and 99%.

Claim 43 (previously presented): The composition as claimed in claim 15, wherein said composition has a fine particle dose of between 60 and 70%.

Claim 44 (previously presented): The composition as claimed in claim 18, wherein the force control agent is included in an amount of less than 10% w/w.

Claim 45 (previously presented): The composition as claimed in claim 18, wherein the force control agent is included in an amount of less than 5% w/w.

Claim 46 (previously presented): The composition as claimed in claim 15, wherein the carrier particles have a particle size of at least 20 μ m.

Claim 47 (new): The composition as claimed in claim 1, wherein the composition comprises 2% to 10% w/w of amino acid.

Claim 48 (new): The composition as claimed in claim 1, wherein the composition comprises 2% to 70% w/w of amino acid.